Use of Direct Oral Anticoagulants in Special Populations

Mar 1, 2017 by in HEMATOLOGY Comments Off on Use of Direct Oral Anticoagulants in Special Populations

Direct oral anticoagulants (DOACs) have been approved for the treatment of venous thromboembolism and atrial fibrillation based on randomized controlled trials (RCTs) of direct comparisons with vitamin K antagonists. Despite…

read more

Perioperative Management of the Direct Oral Anticoagulants

Mar 1, 2017 by in HEMATOLOGY Comments Off on Perioperative Management of the Direct Oral Anticoagulants

The periprocedural management of patients on direct oral anticoagulants (DOACs) is a common but potentially challenging clinical problem because there are few prospective studies to guide clinical decisions. Retrospective analyses…

read more

Direct Oral Anticoagulants

Mar 1, 2017 by in HEMATOLOGY Comments Off on Direct Oral Anticoagulants

In some clinical settings laboratory measurement of direct oral anticoagulants effect is helpful in guiding medical care, such as life-threatening bleeding, need for emergency surgery, renal impairment, severe hepatic failure,…

read more

The History of Antithrombotic Therapy

Mar 1, 2017 by in HEMATOLOGY Comments Off on The History of Antithrombotic Therapy

Key points • The administration of intravenous heparin to a small number of postoperative patients by Barritt and Jordan dramatically reduced the incidence of fatal and nonfatal pulmonary embolism and…

read more

Direct Oral Anticoagulants in Clinical Practice

Mar 1, 2017 by in HEMATOLOGY Comments Off on Direct Oral Anticoagulants in Clinical Practice

Jean Marie Connors, MD, Editor Anticoagulant choices have increased exponentially in the last few years, with new options available for the prevention and treatment of thrombotic disease. Unlike heparin and…

read more

The Challenge of Primary Central Nervous System Lymphoma

Mar 1, 2017 by in HEMATOLOGY Comments Off on The Challenge of Primary Central Nervous System Lymphoma

Primary central nervous system (CNS) lymphoma is a challenging subtypes of aggressive non-Hodgkin lymphoma. Emerging clinical data suggest that optimized outcomes are achieved with dose-intensive CNS-penetrant chemotherapy and avoiding whole…

read more
Get Clinical Tree app for offline access